Scroll

foscarnet 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
insecticides, anthelminthics, pesticides etc., phosphorous derivatives	1241	4428-95-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: foscavir foscarnet phosphonocarboxylic acid phosphonoformic acid foscarnet sodium foscarnet sodium hydrate	An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. Molecular weight: 126.00 Formula: CH3O5P CLOGP: -2.17 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 94.83 ALOGS: -0.88 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

foscavir
foscarnet
phosphonocarboxylic acid
phosphonoformic acid
foscarnet sodium
foscarnet sodium hydrate

An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.

Molecular weight: 126.00
Formula: CH3O5P
CLOGP: -2.17
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 94.83
ALOGS: -0.88
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
6.50	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	952.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	9 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	82 %	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	4.70 hours	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	24 mg/mL	Bocci G, Oprea TI, Benet LZ
CL (Clearance)	2.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.50 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
March 26, 2019	PMDA	CLINIGEN K.K.
Sept. 27, 1991	FDA	CLINIGEN HLTHCARE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	485.65	41.40	138	4140	22795	63461949
Pathogen resistance	440.79	41.40	99	4179	6299	63478445
Encephalitis cytomegalovirus	245.78	41.40	41	4237	520	63484224
Cytomegalovirus viraemia	229.27	41.40	57	4221	5592	63479152
Cytomegalovirus infection	221.01	41.40	74	4204	20878	63463866
Nephropathy toxic	195.52	41.40	56	4222	9423	63475321
Off label use	143.14	41.40	199	4079	674263	62810481
Transplant dysfunction	114.99	41.40	32	4246	4840	63479904
Graft versus host disease in gastrointestinal tract	113.09	41.40	29	4249	3212	63481532
Multiple organ dysfunction syndrome	109.38	41.40	60	4218	56692	63428052

Showing 1 to 10 of 36 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	440.46	31.83	160	5100	25767	34925904
Pathogen resistance	248.19	31.83	81	5179	9401	34942270
Cytomegalovirus viraemia	229.49	31.83	72	5188	7358	34944313
Off label use	172.05	31.83	258	5002	419266	34532405
Encephalitis cytomegalovirus	143.47	31.83	30	5230	588	34951083
Pneumonia cytomegaloviral	134.80	31.83	39	5221	3015	34948656
Nephropathy toxic	119.07	31.83	51	5209	12537	34939134
Cytomegalovirus infection	110.48	31.83	61	5199	26074	34925597
Cytomegalovirus chorioretinitis	107.49	31.83	34	5226	3555	34948116
Renal impairment	106.06	31.83	98	5162	94415	34857256

Showing 1 to 10 of 41 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	920.20	32.13	293	8803	41920	79693372
Pathogen resistance	646.00	32.13	175	8921	14167	79721125
Cytomegalovirus viraemia	406.71	32.13	119	8977	12702	79722590
Encephalitis cytomegalovirus	369.98	32.13	70	9026	1080	79734212
Cytomegalovirus infection	296.28	32.13	128	8968	42516	79692776
Off label use	291.97	32.13	430	8666	906785	78828507
Nephropathy toxic	290.18	32.13	103	8993	20316	79714976
Renal impairment	197.78	32.13	155	8941	157628	79577664
Pneumonia cytomegaloviral	188.24	32.13	53	9043	4916	79730376
Pancytopenia	166.10	32.13	143	8953	165602	79569690

Showing 1 to 10 of 79 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J05AD01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Phosphonic acid derivatives
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:53756	reverse transcriptase inhibitors
CHEBI has role	CHEBI:63330	Na-Pi inhibitor
CHEBI has role	CHEBI:176497	geroprotectors
FDA EPC	N0000175470	Pyrophosphate Analog DNA Polymerase Inhibitor
FDA EXT	N0000175469	Pyrophosphate Analog
FDA MoA	N0000000087	Chelating Activity
FDA MoA	N0000020060	DNA Polymerase Inhibitors
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 10 of 14 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Encephalitis caused by human herpesvirus 6 infection	indication	441512004
Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients	indication
CMV Retinitis in AIDS Patients	indication
Herpes zoster associated with AIDS	off-label use	422127002
Acyclovir-Resistant HSV Infections	off-label use
CMV-Related Polyradiculopathy in AIDS Patients	off-label use
Prevention of Cytomegalovirus Disease	off-label use
Hypophosphatemia	contraindication	4996001
Hypocalcemia	contraindication	5291005
Hyperphosphatemia	contraindication	20165001	DOID:0050459

Showing 1 to 10 of 21 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.44	acidic
pKa2	3.41	acidic
pKa3	5.49	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
DNA polymerase catalytic subunit	Enzyme	DPOL_HHV11	INHIBITOR	IC50	4.13	CHEMBL	CHEMBL
DNA polymerase catalytic subunit	Enzyme	DPOL_HCMVA		IC50	5.60	CHEMBL
Reverse transcriptase/RNaseH	Enzyme	Q72547_9HIV1		IC50	5.69	CHEMBL
Reverse transcriptase	Enzyme	Q9WKE8_9HIV1		IC50	5.60	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
PPF	PDB_CHEM_ID
003605	NDDF
006662	NDDF
225811	RXNORM
306	MMSL
3415	PUBCHEM_CID
34156-56-4	SECONDARY_CAS_RN
364P9RVW4X	UNII
372902006	SNOMEDCT_US
4020530	VANDF

Showing 1 to 10 of 23 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Foscarnet	HUMAN PRESCRIPTION DRUG LABEL	1	63323-875	INJECTION, SOLUTION	24 mg	INTRAVENOUS	ANDA	23 sections
foscarnet sodium	HUMAN PRESCRIPTION DRUG LABEL	1	23155-771	INJECTION, SOLUTION	24 mg	INTRAVENOUS	ANDA	20 sections
Foscarnet Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	25021-189	INJECTION, SOLUTION	24 mg	INTRAVENOUS	ANDA	25 sections
FOSCARNET SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	43066-089	INJECTION, SOLUTION	6000 mg	INTRAVENOUS	ANDA	22 sections
Foscarnet Sodium	Human Prescription Drug Label	1	68083-389	INJECTION, SOLUTION	24 mg	INTRAVENOUS	ANDA	21 sections
Foscavir	HUMAN PRESCRIPTION DRUG LABEL	1	76310-024	INJECTION, SOLUTION	24 mg	INTRAVENOUS	NDA	24 sections
Foscavir	HUMAN PRESCRIPTION DRUG LABEL	1	76310-024	INJECTION, SOLUTION	24 mg	INTRAVENOUS	NDA	24 sections
Foscavir	HUMAN PRESCRIPTION DRUG LABEL	1	76310-024	INJECTION, SOLUTION	24 mg	INTRAVENOUS	NDA	24 sections
Foscavir	HUMAN PRESCRIPTION DRUG LABEL	1	76310-024	INJECTION, SOLUTION	24 mg	INTRAVENOUS	NDA	24 sections
Foscavir	HUMAN PRESCRIPTION DRUG LABEL	1	76310-024	INJECTION, SOLUTION	24 mg	INTRAVENOUS	NDA	24 sections

Showing 1 to 10 of 11 entries

Previous1 2Next